Skip to main content

Laila Asskour

Institutions of which they are part

Research technician
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Laila Asskour

Institutions of which they are part

Research technician
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Projects

(PREDIMIGRAINE) Medicina de precisión para prevenir la cronificación de la migraña a través de la predicción de las crisis de dolor y de la respuesta al tratamiento con anticuerpos anti-CGRP utilizando estrategias multi-ómicas.

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour , Eulalia Gine Cipres, Victor José Gallardo Lopez, Nara Ikumi Montserrat, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 369930
Reference: PMP22/00189
Duration: 01/01/2023 - 30/06/2026

BiOmarcadores Moleculares y clínicos de respuesta al tratamiento en los Ataques de Migraña (Estudio MAMBO).

IP: Marta Torres Ferrús
Collaborators: Alicia Alpuente Ruiz, Laila Asskour , Eulalia Gine Cipres, Victor José Gallardo Lopez, Laura Gómez Dabó, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 75020
Reference: PI22/01530
Duration: 01/01/2023 - 30/06/2026

Cefalea i dolor neurològic

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour , Eulalia Gine Cipres, Marta Torres Ferrús, Victor José Gallardo Lopez, Nara Ikumi Montserrat, Marta Vila Pueyo, Erika Ivanna Araya, Edoardo Caronna
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00406
Duration: 01/01/2022 - 30/06/2025

Fenotipado molecular de pacientes con migrañA según edad y Sexo a través de la cuanTificación de CGRP en saliva para realizar medicina de precisión: estudio FAST.

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour , Eulalia Gine Cipres, Victor José Gallardo Lopez, Laura Gómez Dabó, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 81070
Reference: PI22/01501
Duration: 01/01/2023 - 31/12/2026

Related news

On April 18 and 19, the Vall d’Hebron Research Institute (VHIR) will once again join the Science Festival 2026 with a diverse and participatory program focused on health, innovation, and citizen engagement in research.

The treatment with fremanezumab becomes the first approved therapy to demonstrate efficacy in children and adolescents, a key stage of life as it is one of the most disabling and concentrates the peak incidence of the disease.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Joan Joseph Munné

Joan Joseph Munné

Main researcher
Microbiology
Read more
Juan Ignacio Esteban Mur

Juan Ignacio Esteban Mur

Main researcher
Liver Diseases
Read more
Nuria Nogués Gálvez

Nuria Nogués Gálvez

Senior researcher
Transfusional Medicine
Read more
Mireia Caralt Barba

Mireia Caralt Barba

Senior researcher
General Surgery
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.